IL253479A0 - Crystalline forms of efinconazole - Google Patents

Crystalline forms of efinconazole

Info

Publication number
IL253479A0
IL253479A0 IL253479A IL25347917A IL253479A0 IL 253479 A0 IL253479 A0 IL 253479A0 IL 253479 A IL253479 A IL 253479A IL 25347917 A IL25347917 A IL 25347917A IL 253479 A0 IL253479 A0 IL 253479A0
Authority
IL
Israel
Prior art keywords
efinaconazole
crystalline forms
crystalline
forms
Prior art date
Application number
IL253479A
Other languages
English (en)
Hebrew (he)
Inventor
Adin Itai
Hila Elazari-Shalom
Ori Rorilk
Yana Sery
Original Assignee
Perrigo Api Ltd
Adin Itai
Elazari Shalom Hila
Ori Rorilk
Yana Sery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perrigo Api Ltd, Adin Itai, Elazari Shalom Hila, Ori Rorilk, Yana Sery filed Critical Perrigo Api Ltd
Publication of IL253479A0 publication Critical patent/IL253479A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL253479A 2015-01-20 2017-07-13 Crystalline forms of efinconazole IL253479A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562105390P 2015-01-20 2015-01-20
PCT/IL2015/051171 WO2016116919A1 (en) 2015-01-20 2015-12-02 Crystalline forms of efinaconazole

Publications (1)

Publication Number Publication Date
IL253479A0 true IL253479A0 (en) 2017-09-28

Family

ID=56416514

Family Applications (1)

Application Number Title Priority Date Filing Date
IL253479A IL253479A0 (en) 2015-01-20 2017-07-13 Crystalline forms of efinconazole

Country Status (8)

Country Link
US (1) US20180002310A1 (enExample)
EP (1) EP3247399A4 (enExample)
JP (1) JP2018502165A (enExample)
CN (1) CN107427585A (enExample)
AU (1) AU2015379251A1 (enExample)
CA (1) CA2974180A1 (enExample)
IL (1) IL253479A0 (enExample)
WO (1) WO2016116919A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995434A (zh) * 2016-01-25 2017-08-01 广东东阳光药业有限公司 一种三唑类抗真菌药的晶型及其制备方法
CN110770220B (zh) * 2017-05-19 2022-08-12 科研制药株式会社 艾菲康唑的制备及提纯方法
JP2022515696A (ja) * 2018-12-29 2022-02-22 威智医薬有限公司 エフィナコナゾールの調製方法
JP2021054781A (ja) * 2019-09-26 2021-04-08 デボン エルエス,リミテッド 共結晶形エフィナコナゾール、及びその製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3437695B2 (ja) * 1993-05-10 2003-08-18 科研製薬株式会社 アゾリルアミン誘導体
CN1046278C (zh) * 1993-05-10 1999-11-10 科研制药株式会社 吡咯胺衍生物
PT1205559E (pt) * 1999-07-28 2009-08-04 Kaken Pharma Co Ltd Método para detectar microrganismos patogénicos e agentes antimicrobianos, método para avaliar o efeito medicamentoso de agentes antimicrobianos e agentes antimicrobianos
WO2008081940A1 (ja) * 2006-12-28 2008-07-10 Kaken Pharmaceutical Co., Ltd. 真菌症治療用ゲル組成物
WO2008124131A1 (en) * 2007-04-05 2008-10-16 The John Hopkins University Antifungal agents as neuroprotectants
US20090175810A1 (en) * 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
FR2938066B1 (fr) * 2008-11-06 2010-12-17 Centre Nat Rech Scient Systeme et procede d'analyse quantitative de la composition elementaire de la matiere par spectroscopie du plasma induit par laser (libs)
DK2612859T3 (en) * 2010-08-31 2015-10-19 Kaken Pharma Co Ltd PROCEDURE FOR PREPARING 1-TRIAZOL-2-BUTANOL DERIVATE.
CN104292214B (zh) * 2014-09-24 2017-04-05 南京华威医药科技开发有限公司 艾氟康唑及其中间体的合成方法
CN104327047B (zh) * 2014-10-17 2016-04-06 苏州明锐医药科技有限公司 艾菲康唑的制备方法
AU2016261273A1 (en) * 2015-05-12 2017-12-07 Lupin Limited Process for the preparation of efinaconazole
US10125115B2 (en) * 2015-06-04 2018-11-13 Glenmark Pharmaceuticals Limited Process for the preparation of efinaconazole

Also Published As

Publication number Publication date
EP3247399A1 (en) 2017-11-29
AU2015379251A1 (en) 2017-07-27
WO2016116919A1 (en) 2016-07-28
CA2974180A1 (en) 2016-07-28
US20180002310A1 (en) 2018-01-04
EP3247399A4 (en) 2018-09-05
JP2018502165A (ja) 2018-01-25
CN107427585A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
SG11201706729SA (en) Derivatives of sobetirome
EP3136857A4 (en) Crystalline form of baricitinib
IL257026A (en) Solid state forms of eluxadoline
SG10201913200XA (en) Crystalline form of lorlatinib free base
IL246385A0 (en) Crystalline forms of efitinib di-malate
SI3380554T2 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
PL3113773T3 (pl) Krystaliczne postaci grapiprantu
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
SG10201911417PA (en) Crystalline compounds
ZA201906464B (en) Crystalline forms of (s)-afoxolaner
ZA201706282B (en) Solid forms of menaquinols
PL3532457T3 (pl) Postacie krystaliczne hydroksynorketaminy
HUE066360T2 (hu) Eravaciklin kristályformái
GB201419174D0 (en) Crystalline forms
IL265445A (en) crystalline forms
IL253479A0 (en) Crystalline forms of efinconazole
IL270961A (en) Crystalline form of N-butyldeoxygalactonogirimycin
PL3350179T3 (pl) Krystaliczne postacie
GB201518589D0 (en) Crystalline form of tetraacetylethylenediamine
HK40101405A (zh) C21H22Cl2N4O2的晶型
HUP1500506A2 (en) Salts of palbociclib
IL270937A (en) Crystalline forms of saltalicib
ZA201902553B (en) Crystalline forms